Structure, mechanism and therapeutic utility of immunosuppressive oligonucleotides
Immunotherapeutic activity of Suppressive ODNs. Broadly acting Suppressive ODN A151 ameliorates symptoms of many inflammatory and autoimmune diseases (shown in red). TLR specific Suppressive ODNs have more limited therapeutic utility (shown in blue).
Gespeichert in:
| Autor*in: |
Bayik, Defne [verfasserIn] |
|---|
| Format: |
E-Artikel |
|---|---|
| Sprache: |
Englisch |
| Erschienen: |
2016 |
|---|
| Schlagwörter: |
|---|
| Umfang: |
10 |
|---|
| Übergeordnetes Werk: |
Enthalten in: Social insurance premiums and corporate cash holdings: Evidence from social insurance law in China - Deng, Lixing ELSEVIER, 2022, the official journal of the Italian Pharmacological Society, London |
|---|---|
| Übergeordnetes Werk: |
volume:105 ; year:2016 ; pages:216-225 ; extent:10 |
| Links: |
|---|
| DOI / URN: |
10.1016/j.phrs.2015.11.010 |
|---|
| Katalog-ID: |
ELV035486317 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | ELV035486317 | ||
| 003 | DE-627 | ||
| 005 | 20230624022525.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 180603s2016 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.phrs.2015.11.010 |2 doi | |
| 028 | 5 | 2 | |a GBVA2016018000018.pica |
| 035 | |a (DE-627)ELV035486317 | ||
| 035 | |a (ELSEVIER)S1043-6618(15)30165-1 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 082 | 0 | |a 610 | |
| 082 | 0 | 4 | |a 610 |q DE-600 |
| 082 | 0 | 4 | |a 330 |q VZ |
| 100 | 1 | |a Bayik, Defne |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Structure, mechanism and therapeutic utility of immunosuppressive oligonucleotides |
| 264 | 1 | |c 2016 | |
| 300 | |a 10 | ||
| 336 | |a nicht spezifiziert |b zzz |2 rdacontent | ||
| 337 | |a nicht spezifiziert |b z |2 rdamedia | ||
| 338 | |a nicht spezifiziert |b zu |2 rdacarrier | ||
| 520 | |a Immunotherapeutic activity of Suppressive ODNs. Broadly acting Suppressive ODN A151 ameliorates symptoms of many inflammatory and autoimmune diseases (shown in red). TLR specific Suppressive ODNs have more limited therapeutic utility (shown in blue). | ||
| 650 | 7 | |a CpG oligonucleotide |2 Elsevier | |
| 650 | 7 | |a Dendritic cell |2 Elsevier | |
| 650 | 7 | |a TLR9 |2 Elsevier | |
| 650 | 7 | |a IRF8 |2 Elsevier | |
| 650 | 7 | |a IRF5 |2 Elsevier | |
| 700 | 1 | |a Gursel, Ihsan |4 oth | |
| 700 | 1 | |a Klinman, Dennis M. |4 oth | |
| 773 | 0 | 8 | |i Enthalten in |n Academic Press |a Deng, Lixing ELSEVIER |t Social insurance premiums and corporate cash holdings: Evidence from social insurance law in China |d 2022 |d the official journal of the Italian Pharmacological Society |g London |w (DE-627)ELV008224951 |
| 773 | 1 | 8 | |g volume:105 |g year:2016 |g pages:216-225 |g extent:10 |
| 856 | 4 | 0 | |u https://doi.org/10.1016/j.phrs.2015.11.010 |3 Volltext |
| 912 | |a GBV_USEFLAG_U | ||
| 912 | |a GBV_ELV | ||
| 912 | |a SYSFLAG_U | ||
| 951 | |a AR | ||
| 952 | |d 105 |j 2016 |h 216-225 |g 10 | ||
| 953 | |2 045F |a 610 | ||
| author_variant |
d b db |
|---|---|
| matchkey_str |
bayikdefnegurselihsanklinmandennism:2016----:tutrmcaimnteaetctltoimnsprs |
| hierarchy_sort_str |
2016 |
| publishDate |
2016 |
| allfields |
10.1016/j.phrs.2015.11.010 doi GBVA2016018000018.pica (DE-627)ELV035486317 (ELSEVIER)S1043-6618(15)30165-1 DE-627 ger DE-627 rakwb eng 610 610 DE-600 330 VZ Bayik, Defne verfasserin aut Structure, mechanism and therapeutic utility of immunosuppressive oligonucleotides 2016 10 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Immunotherapeutic activity of Suppressive ODNs. Broadly acting Suppressive ODN A151 ameliorates symptoms of many inflammatory and autoimmune diseases (shown in red). TLR specific Suppressive ODNs have more limited therapeutic utility (shown in blue). CpG oligonucleotide Elsevier Dendritic cell Elsevier TLR9 Elsevier IRF8 Elsevier IRF5 Elsevier Gursel, Ihsan oth Klinman, Dennis M. oth Enthalten in Academic Press Deng, Lixing ELSEVIER Social insurance premiums and corporate cash holdings: Evidence from social insurance law in China 2022 the official journal of the Italian Pharmacological Society London (DE-627)ELV008224951 volume:105 year:2016 pages:216-225 extent:10 https://doi.org/10.1016/j.phrs.2015.11.010 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U AR 105 2016 216-225 10 045F 610 |
| spelling |
10.1016/j.phrs.2015.11.010 doi GBVA2016018000018.pica (DE-627)ELV035486317 (ELSEVIER)S1043-6618(15)30165-1 DE-627 ger DE-627 rakwb eng 610 610 DE-600 330 VZ Bayik, Defne verfasserin aut Structure, mechanism and therapeutic utility of immunosuppressive oligonucleotides 2016 10 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Immunotherapeutic activity of Suppressive ODNs. Broadly acting Suppressive ODN A151 ameliorates symptoms of many inflammatory and autoimmune diseases (shown in red). TLR specific Suppressive ODNs have more limited therapeutic utility (shown in blue). CpG oligonucleotide Elsevier Dendritic cell Elsevier TLR9 Elsevier IRF8 Elsevier IRF5 Elsevier Gursel, Ihsan oth Klinman, Dennis M. oth Enthalten in Academic Press Deng, Lixing ELSEVIER Social insurance premiums and corporate cash holdings: Evidence from social insurance law in China 2022 the official journal of the Italian Pharmacological Society London (DE-627)ELV008224951 volume:105 year:2016 pages:216-225 extent:10 https://doi.org/10.1016/j.phrs.2015.11.010 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U AR 105 2016 216-225 10 045F 610 |
| allfields_unstemmed |
10.1016/j.phrs.2015.11.010 doi GBVA2016018000018.pica (DE-627)ELV035486317 (ELSEVIER)S1043-6618(15)30165-1 DE-627 ger DE-627 rakwb eng 610 610 DE-600 330 VZ Bayik, Defne verfasserin aut Structure, mechanism and therapeutic utility of immunosuppressive oligonucleotides 2016 10 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Immunotherapeutic activity of Suppressive ODNs. Broadly acting Suppressive ODN A151 ameliorates symptoms of many inflammatory and autoimmune diseases (shown in red). TLR specific Suppressive ODNs have more limited therapeutic utility (shown in blue). CpG oligonucleotide Elsevier Dendritic cell Elsevier TLR9 Elsevier IRF8 Elsevier IRF5 Elsevier Gursel, Ihsan oth Klinman, Dennis M. oth Enthalten in Academic Press Deng, Lixing ELSEVIER Social insurance premiums and corporate cash holdings: Evidence from social insurance law in China 2022 the official journal of the Italian Pharmacological Society London (DE-627)ELV008224951 volume:105 year:2016 pages:216-225 extent:10 https://doi.org/10.1016/j.phrs.2015.11.010 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U AR 105 2016 216-225 10 045F 610 |
| allfieldsGer |
10.1016/j.phrs.2015.11.010 doi GBVA2016018000018.pica (DE-627)ELV035486317 (ELSEVIER)S1043-6618(15)30165-1 DE-627 ger DE-627 rakwb eng 610 610 DE-600 330 VZ Bayik, Defne verfasserin aut Structure, mechanism and therapeutic utility of immunosuppressive oligonucleotides 2016 10 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Immunotherapeutic activity of Suppressive ODNs. Broadly acting Suppressive ODN A151 ameliorates symptoms of many inflammatory and autoimmune diseases (shown in red). TLR specific Suppressive ODNs have more limited therapeutic utility (shown in blue). CpG oligonucleotide Elsevier Dendritic cell Elsevier TLR9 Elsevier IRF8 Elsevier IRF5 Elsevier Gursel, Ihsan oth Klinman, Dennis M. oth Enthalten in Academic Press Deng, Lixing ELSEVIER Social insurance premiums and corporate cash holdings: Evidence from social insurance law in China 2022 the official journal of the Italian Pharmacological Society London (DE-627)ELV008224951 volume:105 year:2016 pages:216-225 extent:10 https://doi.org/10.1016/j.phrs.2015.11.010 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U AR 105 2016 216-225 10 045F 610 |
| allfieldsSound |
10.1016/j.phrs.2015.11.010 doi GBVA2016018000018.pica (DE-627)ELV035486317 (ELSEVIER)S1043-6618(15)30165-1 DE-627 ger DE-627 rakwb eng 610 610 DE-600 330 VZ Bayik, Defne verfasserin aut Structure, mechanism and therapeutic utility of immunosuppressive oligonucleotides 2016 10 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Immunotherapeutic activity of Suppressive ODNs. Broadly acting Suppressive ODN A151 ameliorates symptoms of many inflammatory and autoimmune diseases (shown in red). TLR specific Suppressive ODNs have more limited therapeutic utility (shown in blue). CpG oligonucleotide Elsevier Dendritic cell Elsevier TLR9 Elsevier IRF8 Elsevier IRF5 Elsevier Gursel, Ihsan oth Klinman, Dennis M. oth Enthalten in Academic Press Deng, Lixing ELSEVIER Social insurance premiums and corporate cash holdings: Evidence from social insurance law in China 2022 the official journal of the Italian Pharmacological Society London (DE-627)ELV008224951 volume:105 year:2016 pages:216-225 extent:10 https://doi.org/10.1016/j.phrs.2015.11.010 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U AR 105 2016 216-225 10 045F 610 |
| language |
English |
| source |
Enthalten in Social insurance premiums and corporate cash holdings: Evidence from social insurance law in China London volume:105 year:2016 pages:216-225 extent:10 |
| sourceStr |
Enthalten in Social insurance premiums and corporate cash holdings: Evidence from social insurance law in China London volume:105 year:2016 pages:216-225 extent:10 |
| format_phy_str_mv |
Article |
| institution |
findex.gbv.de |
| topic_facet |
CpG oligonucleotide Dendritic cell TLR9 IRF8 IRF5 |
| dewey-raw |
610 |
| isfreeaccess_bool |
false |
| container_title |
Social insurance premiums and corporate cash holdings: Evidence from social insurance law in China |
| authorswithroles_txt_mv |
Bayik, Defne @@aut@@ Gursel, Ihsan @@oth@@ Klinman, Dennis M. @@oth@@ |
| publishDateDaySort_date |
2016-01-01T00:00:00Z |
| hierarchy_top_id |
ELV008224951 |
| dewey-sort |
3610 |
| id |
ELV035486317 |
| language_de |
englisch |
| fullrecord |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">ELV035486317</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230624022525.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">180603s2016 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1016/j.phrs.2015.11.010</subfield><subfield code="2">doi</subfield></datafield><datafield tag="028" ind1="5" ind2="2"><subfield code="a">GBVA2016018000018.pica</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)ELV035486317</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(ELSEVIER)S1043-6618(15)30165-1</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="082" ind1="0" ind2=" "><subfield code="a">610</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">DE-600</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">330</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Bayik, Defne</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Structure, mechanism and therapeutic utility of immunosuppressive oligonucleotides</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2016</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">10</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zzz</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">z</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zu</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Immunotherapeutic activity of Suppressive ODNs. Broadly acting Suppressive ODN A151 ameliorates symptoms of many inflammatory and autoimmune diseases (shown in red). TLR specific Suppressive ODNs have more limited therapeutic utility (shown in blue).</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">CpG oligonucleotide</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Dendritic cell</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">TLR9</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">IRF8</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">IRF5</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Gursel, Ihsan</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Klinman, Dennis M.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="n">Academic Press</subfield><subfield code="a">Deng, Lixing ELSEVIER</subfield><subfield code="t">Social insurance premiums and corporate cash holdings: Evidence from social insurance law in China</subfield><subfield code="d">2022</subfield><subfield code="d">the official journal of the Italian Pharmacological Society</subfield><subfield code="g">London</subfield><subfield code="w">(DE-627)ELV008224951</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:105</subfield><subfield code="g">year:2016</subfield><subfield code="g">pages:216-225</subfield><subfield code="g">extent:10</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1016/j.phrs.2015.11.010</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ELV</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_U</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">105</subfield><subfield code="j">2016</subfield><subfield code="h">216-225</subfield><subfield code="g">10</subfield></datafield><datafield tag="953" ind1=" " ind2=" "><subfield code="2">045F</subfield><subfield code="a">610</subfield></datafield></record></collection>
|
| author |
Bayik, Defne |
| spellingShingle |
Bayik, Defne ddc 610 ddc 330 Elsevier CpG oligonucleotide Elsevier Dendritic cell Elsevier TLR9 Elsevier IRF8 Elsevier IRF5 Structure, mechanism and therapeutic utility of immunosuppressive oligonucleotides |
| authorStr |
Bayik, Defne |
| ppnlink_with_tag_str_mv |
@@773@@(DE-627)ELV008224951 |
| format |
electronic Article |
| dewey-ones |
610 - Medicine & health 330 - Economics |
| delete_txt_mv |
keep |
| author_role |
aut |
| collection |
elsevier |
| remote_str |
true |
| illustrated |
Not Illustrated |
| topic_title |
610 610 DE-600 330 VZ Structure, mechanism and therapeutic utility of immunosuppressive oligonucleotides CpG oligonucleotide Elsevier Dendritic cell Elsevier TLR9 Elsevier IRF8 Elsevier IRF5 Elsevier |
| topic |
ddc 610 ddc 330 Elsevier CpG oligonucleotide Elsevier Dendritic cell Elsevier TLR9 Elsevier IRF8 Elsevier IRF5 |
| topic_unstemmed |
ddc 610 ddc 330 Elsevier CpG oligonucleotide Elsevier Dendritic cell Elsevier TLR9 Elsevier IRF8 Elsevier IRF5 |
| topic_browse |
ddc 610 ddc 330 Elsevier CpG oligonucleotide Elsevier Dendritic cell Elsevier TLR9 Elsevier IRF8 Elsevier IRF5 |
| format_facet |
Elektronische Aufsätze Aufsätze Elektronische Ressource |
| format_main_str_mv |
Text Zeitschrift/Artikel |
| carriertype_str_mv |
zu |
| author2_variant |
i g ig d m k dm dmk |
| hierarchy_parent_title |
Social insurance premiums and corporate cash holdings: Evidence from social insurance law in China |
| hierarchy_parent_id |
ELV008224951 |
| dewey-tens |
610 - Medicine & health 330 - Economics |
| hierarchy_top_title |
Social insurance premiums and corporate cash holdings: Evidence from social insurance law in China |
| isfreeaccess_txt |
false |
| familylinks_str_mv |
(DE-627)ELV008224951 |
| title |
Structure, mechanism and therapeutic utility of immunosuppressive oligonucleotides |
| ctrlnum |
(DE-627)ELV035486317 (ELSEVIER)S1043-6618(15)30165-1 |
| title_full |
Structure, mechanism and therapeutic utility of immunosuppressive oligonucleotides |
| author_sort |
Bayik, Defne |
| journal |
Social insurance premiums and corporate cash holdings: Evidence from social insurance law in China |
| journalStr |
Social insurance premiums and corporate cash holdings: Evidence from social insurance law in China |
| lang_code |
eng |
| isOA_bool |
false |
| dewey-hundreds |
600 - Technology 300 - Social sciences |
| recordtype |
marc |
| publishDateSort |
2016 |
| contenttype_str_mv |
zzz |
| container_start_page |
216 |
| author_browse |
Bayik, Defne |
| container_volume |
105 |
| physical |
10 |
| class |
610 610 DE-600 330 VZ |
| format_se |
Elektronische Aufsätze |
| author-letter |
Bayik, Defne |
| doi_str_mv |
10.1016/j.phrs.2015.11.010 |
| dewey-full |
610 330 |
| title_sort |
structure, mechanism and therapeutic utility of immunosuppressive oligonucleotides |
| title_auth |
Structure, mechanism and therapeutic utility of immunosuppressive oligonucleotides |
| abstract |
Immunotherapeutic activity of Suppressive ODNs. Broadly acting Suppressive ODN A151 ameliorates symptoms of many inflammatory and autoimmune diseases (shown in red). TLR specific Suppressive ODNs have more limited therapeutic utility (shown in blue). |
| abstractGer |
Immunotherapeutic activity of Suppressive ODNs. Broadly acting Suppressive ODN A151 ameliorates symptoms of many inflammatory and autoimmune diseases (shown in red). TLR specific Suppressive ODNs have more limited therapeutic utility (shown in blue). |
| abstract_unstemmed |
Immunotherapeutic activity of Suppressive ODNs. Broadly acting Suppressive ODN A151 ameliorates symptoms of many inflammatory and autoimmune diseases (shown in red). TLR specific Suppressive ODNs have more limited therapeutic utility (shown in blue). |
| collection_details |
GBV_USEFLAG_U GBV_ELV SYSFLAG_U |
| title_short |
Structure, mechanism and therapeutic utility of immunosuppressive oligonucleotides |
| url |
https://doi.org/10.1016/j.phrs.2015.11.010 |
| remote_bool |
true |
| author2 |
Gursel, Ihsan Klinman, Dennis M. |
| author2Str |
Gursel, Ihsan Klinman, Dennis M. |
| ppnlink |
ELV008224951 |
| mediatype_str_mv |
z |
| isOA_txt |
false |
| hochschulschrift_bool |
false |
| author2_role |
oth oth |
| doi_str |
10.1016/j.phrs.2015.11.010 |
| up_date |
2024-07-06T17:41:06.971Z |
| _version_ |
1803852360683880448 |
| fullrecord_marcxml |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">ELV035486317</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230624022525.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">180603s2016 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1016/j.phrs.2015.11.010</subfield><subfield code="2">doi</subfield></datafield><datafield tag="028" ind1="5" ind2="2"><subfield code="a">GBVA2016018000018.pica</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)ELV035486317</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(ELSEVIER)S1043-6618(15)30165-1</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="082" ind1="0" ind2=" "><subfield code="a">610</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">DE-600</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">330</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Bayik, Defne</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Structure, mechanism and therapeutic utility of immunosuppressive oligonucleotides</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2016</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">10</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zzz</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">z</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zu</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Immunotherapeutic activity of Suppressive ODNs. Broadly acting Suppressive ODN A151 ameliorates symptoms of many inflammatory and autoimmune diseases (shown in red). TLR specific Suppressive ODNs have more limited therapeutic utility (shown in blue).</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">CpG oligonucleotide</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Dendritic cell</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">TLR9</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">IRF8</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">IRF5</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Gursel, Ihsan</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Klinman, Dennis M.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="n">Academic Press</subfield><subfield code="a">Deng, Lixing ELSEVIER</subfield><subfield code="t">Social insurance premiums and corporate cash holdings: Evidence from social insurance law in China</subfield><subfield code="d">2022</subfield><subfield code="d">the official journal of the Italian Pharmacological Society</subfield><subfield code="g">London</subfield><subfield code="w">(DE-627)ELV008224951</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:105</subfield><subfield code="g">year:2016</subfield><subfield code="g">pages:216-225</subfield><subfield code="g">extent:10</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1016/j.phrs.2015.11.010</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ELV</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_U</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">105</subfield><subfield code="j">2016</subfield><subfield code="h">216-225</subfield><subfield code="g">10</subfield></datafield><datafield tag="953" ind1=" " ind2=" "><subfield code="2">045F</subfield><subfield code="a">610</subfield></datafield></record></collection>
|
| score |
7.3967133 |